Medibyte Pharma

What Medibyte Pharma does

Medibyte Pharma is a privately held Indian pharmaceutical manufacturer and PCD (Propaganda Cum Distribution) franchise operator, structured as a division of Dr. Kumars Pharmaceuticals with its registered office and manufacturing facility at Plot No 158, Industrial Area Phase 1, Panchkula, Haryana. The company manufactures 300+ pharmaceutical products across multiple dosage forms — tablets, capsules, soft gelatin capsules, oral liquids/syrups/suspensions, dry syrups, injections, infusions, ointments, protein powders, and sachets — at GMP and WHO-GMP certified facilities, with DCGI-approved product listings for the Indian market. Its portfolio spans antibiotics, analgesics, anti-spasmodics, anti-emetics, antipyretics, digestive enzymes, dermatology, orthopaedics, multivitamins, haematinics, cardiac, diabetic, neurology, psychiatry, gynaecology, ophthalmology, nephrology/urology, paediatrics, and ayurvedic segments.

The company commercialises through 200+ PCD franchise partners across India, each granted exclusive monopoly or distribution rights in a designated territory, who in turn sell to doctors, hospitals, and pharmacies in their regions. Medibyte supports franchisees with promotional tools, visual aids, MR kits, product samples, and regular marketing updates, while maintaining a digital presence through its corporate website and social media channels (Facebook, Twitter/X, LinkedIn, Pinterest). The portfolio is organised into 10+ specialised sub-brand divisions including QnQ Cardia (cardiac/diabetic), QnQ Derma (dermatology), Meditreat (gynaecology), Unibyte Kids (paediatrics), Finoptis (eye/ear), Trucent (nephrology/urology), Medigrant (critical care), Russel Biotech (specialty), Unibyte Ayurveda (ayurvedic), and Biofinity (general). Revenue is generated through one-time franchise license fees and ongoing product sales to franchise partners at wholesale prices, with end-product MRPs ranging from INR 75 to INR 7,950. The company operates with approximately 7 direct employees, no institutional funding, no disclosed revenue, and no stock exchange listing.

Name

Medibyte Pharma

Legal name

Medibyte (Division of Dr. Kumars Pharmaceuticals)

Website

https://medibyte.in

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Medibyte Pharma is an Indian PCD pharma franchise company (division of Dr. Kumars Pharmaceuticals) that manufactures and distributes 300+ generic pharmaceutical products across 10+ therapeutic divisions through 200+ exclusive franchise partners pan-India.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIAAAA

Primary Care & General Medicine Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYCRAOAHAA

Prescription Pharmaceutical (Rx) Wholesale Distribution

Consumer Products & Retail/Wholesale, Distribution & Category Management/Health, OTC & Pharmacy Wholesale Distribution

Keywords

• Pharmaceutical manufacturing
• PCD pharma franchise
• Generic medicines
• Pharmaceutical distribution
• DCGI approved drugs

Headquarters

HQ city

Panchkula

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. PCD Pharma Franchise: The company generates revenue through a PCD (Propaganda Cum Distribution) pharma franchise model. Franchise partners pay for distribution/monopoly rights and purchase pharmaceutical products at wholesale prices for distribution in their assigned territories. The company manufactures and supplies quality medicines while franchise holders market and distribute products in their regions.
2. Pharmaceutical Product Sales: Revenue from sale of pharmaceutical products across various therapeutic segments including Tablets, Capsules, Injections, Syrups, Ointments, and Dry Syrups to franchise partners and customers.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Medibyte Pharma manufactures and distributes a 300+ product portfolio of DCGI-approved pharmaceutical formulations (tablets, capsules, injectables, syrups, dry syrups, eye/ear drops, ointments, infusions, protein powders, sachets) covering antibiotics, analgesics, anti-spasmodics, anti-vomiting, antipyretics, dermatology, ortho, multivitamins, cardiac, diabetic, neurology, gynaecology, paediatrics, and ayurvedic segments. The company sells exclusively through a PCD (Propaganda Cum Distribution) pharma franchise model, granting franchise partners monopoly-based distribution rights in designated Indian territories.

Product overview

Medibyte Pharma is a Chandigarh-based pharmaceutical company and division of Dr. Kumars Pharmaceuticals, operating as a PCD (Propaganda Cum Distribution) Pharma Franchise Company. The company offers a comprehensive portfolio of over 300 pharmaceutical products across multiple therapeutic segments including Antibiotics, Analgesics, Anti-Spasmodic, Anti-Vomiting, Digestive Enzymes, Antipyretic suspensions, Dermatology, Ortho Products, Multivitamins, Cardiology, Diabetology, Neurology, and Gynaecology. The product portfolio spans multiple dosage forms: Tablets (including Alu-Alu, Blister strips), Capsules, Liquids/Oral Syrups, Dry Syrups, Injections, Eye/Ear Drops, Infusions, Ointments, Protein Powders, and Sachets. The company operates through specialized divisions including QnQ Cardia (Cardiac & Diabetic), QnQ Derma (Dermatology), Meditreat (Gynaecology), Unibyte Kids (Paediatrics), Finoptis (Ophthalmic/ENT), Unibyte Ayurveda (Herbal), Trucent (Nephrology), Russel Biotech (Specialty), and Medigrant Critical Care. Medibyte provides monopoly-based PCD franchise opportunities across India, offering DCGI-approved products with GMP and WHO certifications.

Differentiator

Problem solved

Functional benefit

Brands

• Biofinity: General pharmaceutical products division
• QnQ Cardia
• QnQ Derma
• Finoptis
• Meditreat
• Medigrant
• Unibyte Kids
• Russel Biotech
• Trucent
• Unibyte Ayurveda
• Dr. Kumar

Products and services

• PCD Pharma Franchise Program

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Dr. Kumars PharmaceuticalscoreStrategic or Co-development PartnerMedibyte is a division of Dr. Kumars Pharmaceuticals. The parent company is based in Panchkula, Haryana and provides the infrastructure, manufacturing facilities, and brand backing for the Medibyte PCD franchise operations. Dr. Kumars Pharmaceuticals supports Medibyte's manufacturing capabilities with GMP and WHO certified facilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Akums Drugs & Pharmaceuticals: India-based contract and branded pharmaceutical manufacturer producing multiple dosage forms including injectables, tablets, and syrups. Comparable as a domestic Indian manufacturer with overlapping dosage-form and franchise capabilities.

Direct peers

• Macleods Pharmaceuticals: Mumbai-headquartered Indian generic pharma manufacturer with a large multi-therapy portfolio and active PCD/franchise operations across India. Direct comparable on manufacturing breadth, therapeutic coverage, and franchise distribution model.
• Systopic Laboratories: India-based generic pharma manufacturer with broad therapeutic coverage (antibiotics, dermatology, cardiac, etc.) and an active PCD/franchise model. Closely comparable in size segment, product breadth, and franchise distribution approach.
• Aristo Pharmaceuticals: Indian pharma company with a multi-specialty generic portfolio and franchise/PCD distribution across India. Direct comparable on therapeutic breadth, dosage-form coverage, and franchise-led GTM.
• Biochem Pharmaceutical Industries: Mumbai-based Indian pharma manufacturer focused on branded generics with strong franchise/PCD distribution. Comparable on multi-therapy portfolio and franchise-led domestic distribution model.

Broad incumbents

• Mankind Pharma: One of India's largest domestic pharma companies with an extensive branded-generic portfolio and a deep PCD/franchise distribution network across India. Comparable as a broad-based competitor in the same Indian branded-generics and franchise-driven GTM.
• Cipla: One of India's largest pharma companies with a domestic branded-generic franchise across multiple therapy areas. Comparable as a broader incumbent whose branded-generic India business overlaps with Medibyte's therapeutic coverage.
• Zydus Lifesciences: Large Indian pharma group with a branded-generic portfolio spanning cardiac, diabetic, dermatology, and other specialties. Comparable as a broader incumbent with overlapping therapy coverage and franchise distribution.
• Ajanta Pharma: Indian specialty pharma company with branded generics in cardiology, dermatology, ophthalmology, and other segments. Comparable on therapeutic focus areas (especially derma and ophthalmic) and India franchise distribution.
• Alkem Laboratories: Established Indian branded-generic manufacturer with pan-India presence across antibiotics, cardiac, diabetic, and other therapies. Comparable as a larger incumbent operating in many of the same therapy areas Medibyte covers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MedibytesPharma
• Facebookfacebook.com/medibytepcdfranchise
• LinkedInlinkedin.com/company/medibyte-pharma
• Pinterestin.pinterest.com/medibytep

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medibyte Pharma